We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Mass Spectrometry Imaging Used to Process Biologic “Big Data”

By LabMedica International staff writers
Posted on 01 Dec 2014
Print article
The vast amounts of data that are generated by the latest scientific instruments are leading to significant scientific discoveries, but only when scientists can effectively process that data. Big data represents both an opportunity and a challenge for scientists. This is especially the case for analytic scientists studying biologic materials using a fairly new technique known as mass spectrometry imaging (MSI). Help has arrived from a recent project, however, called Computis, which has a range of new tools for effectively processing MSI data.

MSI is a form of mass spectrometry (MS) that enables both spatial and mass spectrometric analysis by measuring the masses of compounds at specific locations on the surface of a solid sample. MSI can, therefore, construct a visual image of its chemical composition. Various MSI techniques are available, including matrix-assisted laser desorption/ionization (MALDI), secondary ion MS (SIMS) and desorption electrospray ionization (DESI), but they all generate huge amounts of data.

Although software tools are available for processing this information, they tend to be produced by the manufacturers of the MSI instruments and therefore each uses diverse data formats, making it difficult to combine and process data generated by different instruments. Computis was set up by the European Commission in 2006 to overcome this hurdle by developing a new generation of flexible and efficient tools for processing any MSI data. It involved academic and industrial teams from across Europe, including the French Atomic Energy Commission and the Swiss pharmaceutical giant Novartis (Basel, Switzerland). The project was completed in 2010 and the main outputs have now been described November 2014 in an article in the European Journal of Mass Spectrometry (EJMS).

The project members rapidly figured out that their first task should be to develop a common format for MSI data that all the other data formats could be converted into, which led to the imzML data format. This format divides MSI data into two separate files: the mass data are stored in a binary file to ensure proficient storage, while metadata such as instrumental parameters and sample details are stored in an XML file. The members also developed several tools for translating MSI data in other formats into the imzML format.

The project then developed several tools specially designed to work with the imzML format. This included two tools for processing and displaying MSI data, Data Cube Explorer and SpectViewer, and a tool called EasyReg2D for incorporating MSI data with image data from other analytic instruments, including microscopes. Furthermore, the researchers adapted an existing MSI processing tool known as BioMap to work with data in the imzML format.

According to the investigators, this project has been successful in greatly expanding the tools available for processing MSI data, helping to ensure big data becomes an opportunity for scientists instead of remaining a challenge.

Related Links:

Novartis


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A massive study has identified new biomarkers for renal cancer subtypes, improving diagnosis and treatment (Photo courtesy of Jessica Johnson)

Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes

Renal cell carcinomas (RCCs) are notably diverse, encompassing over 20 distinct subtypes and generally categorized into clear cell and non-clear cell types; around 20% of all RCCs fall into the non-clear... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more